PsygaBio is a drug discovery company focused on developing therapeutics derived from natural compounds. Using Cannasoul's proprietary analytical platform, PsygaBio's data-driven approach, know-how, and clinical trial framework support active compound identification and development, from mushroom cultivation and extraction to clinically approved formulations. PsygaBio, in partnership with Cannasoul Analytics, aims to exploit the diversity found in the psychedelic mushroom realm to identify active compounds and formulations for therapeutic benefits. PsygaBio is a subsidiary of Cannasoul Analytics.